BioHarvest Sciences Inc. (CNVCF) Research

BioHarvest Sciences Inc., along with its subsidiaries, supplies a range of nutraceutical products and medical cannabis to customers both in Israel and globally. The company leverages an innovative plant cell growth technology that allows it to cultivate active secondary metabolites directly from cells, completely circumventing the need to grow the actual plant. BioHarvest is responsible for the entire process, from designing and developing to manufacturing and marketing its offerings. These include Vinia, a nutraceutical powder derived from red grapes, as well as its medical cannabis line. The firm's main operational base is located in Vancouver, Canada.

Market snapshot

Symbol
CNVCF
Price
$6.30
Market cap
$97.3M
P/E ratio
-7.04x
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Recent news

  • BioHarvest Sciences achieves revenue gains and margin expansion, narrows losses in 2025

    BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) has reported its financial results for the fourth quarter and full year 2025, highlighting revenue growth, improved margins, and continued investment in its product and contract manufacturing businesses. The company recorded full-year revenue of $34.5 million, representing a 37% increase compared to 2024.

  • BioHarvest Sciences advances sustainable fragrance production with rare plant breakthrough

    BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has completed the first stage of a multi-phase development program focused on a rare scent-producing plant used in the global fragrance industry. The work was carried out through the company's contract development and manufacturing organization (CDMO) division under an agreement signed about a year ago.

  • BioHarvest Sciences' VINIA gains traction with top spot in US nutraceutical category

    BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said its VINIA product has become the top-selling resveratrol polyphenol nutraceutical brand in the United States, citing company data, as it continues to expand its direct-to-consumer business. The biotechnology company attributed VINIA's market position to its clinically studied ability to support arterial dilation and blood flow, a mechanism it says can enhance oxygen and nutrient delivery throughout the body.

Peer companies

  • Adocia S.A. (ADOIF)
  • Anteris Technologies Ltd (AMEUF)
  • Creso Pharma Limited (COPHF)
  • CSAM Health Group AS (CSAMF)
  • Ecofibre Limited (EOFBY)
  • Eupraxia Pharmaceuticals Inc. (EPRXF)
  • Green Rain Energy Holdings Inc. (GREH)
  • Leafly Holdings, Inc. (LFLY)

Open BioHarvest Sciences Inc. (CNVCF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.